SEHK:175
SEHK:175Auto

Is Geely Automobile Holdings (SEHK:175) Pricing Reflect Its DCF Value After Recent Share Pullback

Wondering if Geely Automobile Holdings is priced attractively after its recent run, or if the easy gains are already gone? This article is going to focus squarely on what the current share price might be implying about value. The stock last closed at HK$17.19, with a 27.3% return over the past year and a 51.4% return over three years. However, the 5.5% return decline over both the past week and year to date, and a 0.8% decline over the past month, show that the ride has not been...
SEHK:1024
SEHK:1024Interactive Media and Services

Is Kuaishou Technology (SEHK:1024) Still Attractively Priced After Its 91% One-Year Rally

If you are wondering whether Kuaishou Technology is attractively priced right now, this article will walk you through how its current share price stacks up against a range of valuation checks. The stock last closed at HK$74.70, with returns of 12.8% over the past week, 11.9% over the past month, 12.8% year to date, and 91.1% over the past year, which may have caught the attention of investors watching for changing risk and reward. Recent attention around Kuaishou has focused on its position...
SEHK:823
SEHK:823Retail REITs

A Look At Link REIT (SEHK:823) Valuation After Extended Interim Leadership And CEO Search Update

Leadership changes and why they matter for Link Real Estate Investment Trust Link Real Estate Investment Trust (SEHK:823) is back in focus after Link Asset Management confirmed an extended interim leadership setup, following the former Group CEO’s departure at the end of 2025. Mr. John Russell Saunders, previously Group Chief Investment Officer, has been appointed Executive Director, working alongside Executive Director and Group Chief Financial Officer Mr. Ng Kok Siong under this temporary...
SEHK:6618
SEHK:6618Consumer Retailing

Why JD Health (SEHK:6618) Is Up 13.3% After Strong Quarterly Results And Analyst Endorsement

CICC recently maintained its Buy rating on JD Health International, Inc. and reiterated confidence in the company following a quarter of strong year-over-year revenue and profit growth. This combination of upbeat analyst commentary and improved financial performance has reinforced investor attention on JD Health’s position in China’s online healthcare market. Now, we’ll explore how this stronger quarterly performance may influence JD Health’s existing investment narrative built around...
SEHK:883
SEHK:883Oil and Gas

CNOOC (SEHK:883) Valuation Check As Buzios6 Production Starts In Brazil

CNOOC (SEHK:883) has reported first oil from the Buzios6 Project in Brazil’s pre salt Buzios field, a large deep water development that lifts the oilfield’s installed capacity to 1.15 million barrels per day. See our latest analysis for CNOOC. Despite the Buzios6 milestone and recent board changes in late December, CNOOC’s HK$20.94 share price sits after a mixed patch, with a 1 day share price return of 1.26% but a 7 day share price return decline of 4.21%, while the 90 day share price return...
SEHK:1208
SEHK:1208Metals and Mining

A Look At MMG (SEHK:1208) Valuation After The Major Khoemacau Copper Mine Expansion Approval

MMG (SEHK:1208) has moved ahead with a major expansion of its Khoemacau Copper Mine in Botswana, committing about US$900 million to increase output capacity and target lower operating costs. See our latest analysis for MMG. That expansion decision comes after a strong run in the stock, with a 30 day share price return of 11.71% and a 90 day share price return of 31.69%, alongside a very large 1 year total shareholder return that points to momentum still building rather than fading. If MMG’s...
SEHK:6855
SEHK:6855Biotechs

A Look At Ascentage Pharma Group International's Valuation After FDA IND Clearance For APG-3288

Ascentage Pharma Group International (SEHK:6855) has drawn fresh attention after announcing that its BTK-targeted protein degrader APG-3288 received U.S. FDA IND clearance, allowing a global Phase I trial in relapsed or refractory B-cell malignancies. See our latest analysis for Ascentage Pharma Group International. The FDA IND clearance for APG-3288 comes as Ascentage Pharma’s share price sits at HK$54.95, with a 1-day share price return of 1.20% and a 7-day share price return of 7.96%,...
SEHK:1177
SEHK:1177Pharmaceuticals

Assessing Sino Biopharmaceutical (SEHK:1177) Valuation After Fresh IPF And Psoriasis Trial Milestones

Sino Biopharmaceutical (SEHK:1177) has just reported two key clinical milestones, including first patient enrollment in a Phase III trial for IPF drug candidate TDI01 and positive Phase II data for psoriasis treatment TQH3906. See our latest analysis for Sino Biopharmaceutical. The latest clinical updates arrive after a mixed year for Sino Biopharmaceutical’s shares. The stock has a 7.39% year-to-date share price return at HK$6.83, a 12.44% decline over 90 days, and a very large 1-year total...
SEHK:8
SEHK:8Telecom

How Investors Are Reacting To PCCW (SEHK:8) Expanding Its FWD Branding And Marketing Partnership

In December 2025, PCCW Interactive Media Holdings Limited, a subsidiary of PCCW, entered into a Branding and Marketing Arrangements Framework Agreement with FWD Life Insurance covering 1 January 2026 to 31 December 2028, under which PCCW Group (including the HKT Group) will provide branding, spokesperson and marketing services charged at market-referenced rates. The agreement is grounded in arm’s length annual caps informed by historical IFRS-recognised service revenues of about US$6.60...